A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Identifieur interne : 002432 ( PubMed/Corpus ); précédent : 002431; suivant : 002433A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Auteurs : Martin Schlumberger ; Barbara Jarzab ; Maria E. Cabanillas ; Bruce Robinson ; Furio Pacini ; Douglas W. Ball ; Judith Mccaffrey ; Kate Newbold ; Roger Allison ; Renato G. Martins ; Lisa F. Licitra ; Manisha H. Shah ; Donald Bodenner ; Rossella Elisei ; Lynn Burmeister ; Yasuhiro Funahashi ; Min Ren ; James P. O'Brien ; Steven I. ShermanSource :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (pharmacology), Antineoplastic Agents (therapeutic use), Biomarkers, Carcinoma, Neuroendocrine (blood), Carcinoma, Neuroendocrine (drug therapy), Carcinoma, Neuroendocrine (pathology), Disease Progression, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Phenylurea Compounds (pharmacology), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (pharmacology), Protein Kinase Inhibitors (therapeutic use), Quinolines (pharmacology), Quinolines (therapeutic use), Retreatment, Thyroid Neoplasms (blood), Thyroid Neoplasms (drug therapy), Thyroid Neoplasms (pathology), Treatment Outcome, Young Adult.
- MESH :
- chemical , pharmacology : Antineoplastic Agents, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- chemical , therapeutic use : Antineoplastic Agents, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- blood : Carcinoma, Neuroendocrine, Thyroid Neoplasms.
- drug therapy : Carcinoma, Neuroendocrine, Thyroid Neoplasms.
- pathology : Carcinoma, Neuroendocrine, Thyroid Neoplasms.
- Adult, Aged, Biomarkers, Disease Progression, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Retreatment, Treatment Outcome, Young Adult.
Abstract
Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).
DOI: 10.1158/1078-0432.CCR-15-1127
PubMed: 26311725
Links to Exploration step
pubmed:26311725Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.</title>
<author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name>
<affiliation><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name>
<affiliation><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name>
<affiliation><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation><nlm:affiliation>Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name>
<affiliation><nlm:affiliation>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name>
<affiliation><nlm:affiliation>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mccaffrey, Judith" sort="Mccaffrey, Judith" uniqKey="Mccaffrey J" first="Judith" last="Mccaffrey">Judith Mccaffrey</name>
<affiliation><nlm:affiliation>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name>
<affiliation><nlm:affiliation>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name>
<affiliation><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name>
<affiliation><nlm:affiliation>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bodenner, Donald" sort="Bodenner, Donald" uniqKey="Bodenner D" first="Donald" last="Bodenner">Donald Bodenner</name>
<affiliation><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name>
<affiliation><nlm:affiliation>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burmeister, Lynn" sort="Burmeister, Lynn" uniqKey="Burmeister L" first="Lynn" last="Burmeister">Lynn Burmeister</name>
<affiliation><nlm:affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name>
<affiliation><nlm:affiliation>Eisai, Andover, Massachusetts.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name>
<affiliation><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name>
<affiliation><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name>
<affiliation><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26311725</idno>
<idno type="pmid">26311725</idno>
<idno type="doi">10.1158/1078-0432.CCR-15-1127</idno>
<idno type="wicri:Area/PubMed/Corpus">002432</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002432</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.</title>
<author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name>
<affiliation><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name>
<affiliation><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name>
<affiliation><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation><nlm:affiliation>Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name>
<affiliation><nlm:affiliation>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name>
<affiliation><nlm:affiliation>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mccaffrey, Judith" sort="Mccaffrey, Judith" uniqKey="Mccaffrey J" first="Judith" last="Mccaffrey">Judith Mccaffrey</name>
<affiliation><nlm:affiliation>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name>
<affiliation><nlm:affiliation>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name>
<affiliation><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name>
<affiliation><nlm:affiliation>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bodenner, Donald" sort="Bodenner, Donald" uniqKey="Bodenner D" first="Donald" last="Bodenner">Donald Bodenner</name>
<affiliation><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name>
<affiliation><nlm:affiliation>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burmeister, Lynn" sort="Burmeister, Lynn" uniqKey="Burmeister L" first="Lynn" last="Burmeister">Lynn Burmeister</name>
<affiliation><nlm:affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name>
<affiliation><nlm:affiliation>Eisai, Andover, Massachusetts.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name>
<affiliation><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name>
<affiliation><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name>
<affiliation><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Biomarkers</term>
<term>Carcinoma, Neuroendocrine (blood)</term>
<term>Carcinoma, Neuroendocrine (drug therapy)</term>
<term>Carcinoma, Neuroendocrine (pathology)</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Phenylurea Compounds (pharmacology)</term>
<term>Phenylurea Compounds (therapeutic use)</term>
<term>Protein Kinase Inhibitors (pharmacology)</term>
<term>Protein Kinase Inhibitors (therapeutic use)</term>
<term>Quinolines (pharmacology)</term>
<term>Quinolines (therapeutic use)</term>
<term>Retreatment</term>
<term>Thyroid Neoplasms (blood)</term>
<term>Thyroid Neoplasms (drug therapy)</term>
<term>Thyroid Neoplasms (pathology)</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Phenylurea Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Phenylurea Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinolines</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Carcinoma, Neuroendocrine</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Neuroendocrine</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Neuroendocrine</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Biomarkers</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Retreatment</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26311725</PMID>
<DateCreated><Year>2016</Year>
<Month>01</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>22</Volume>
<Issue>1</Issue>
<PubDate><Year>2016</Year>
<Month>Jan</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
<ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.</ArticleTitle>
<Pagination><MedlinePgn>44-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-15-1127</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).</AbstractText>
<AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Fifty-nine patients with unresectable progressive MTC per Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 within the prior 12 months received lenvatinib (24-mg daily, 28-day cycles) until disease progression, unmanageable toxicity, withdrawal, or death. Prior anti-VEGFR therapy was permitted. The primary endpoint was objective response rate (ORR) by RECIST v1.0 and independent imaging review.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Lenvatinib ORR was 36% [95% confidence interval (CI), 24%-49%]; all partial responses. ORR was comparable between patients with (35%) or without (36%) prior anti-VEGFR therapy. Disease control rate (DCR) was 80% (95% CI, 67%-89%); 44% had stable disease. Among responders, median time to response (TTR) was 3.5 months (95% CI, 1.9-3.7). Median progression-free survival (PFS) was 9.0 months (95% CI, 7.0-not evaluable). Common toxicity criteria grade 3/4 treatment-emergent adverse events included diarrhea (14%), hypertension (7%), decreased appetite (7%), fatigue, dysphagia, and increased alanine aminotransferase levels (5% each). Ret proto-oncogene status did not correlate with outcomes. Low baseline levels of angiopoietin-2, hepatocyte growth factor, and IL8 were associated with tumor reduction and prolonged PFS. High baseline levels of VEGF, soluble VEGFR3, and platelet-derived growth factor BB, and low baseline levels of soluble Tie-2, were associated with tumor reduction.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lenvatinib had a high ORR, high DCR, and a short TTR in patients with documented progressive MTC. Toxicities were managed with dose modifications and medications.</AbstractText>
<CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schlumberger</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jarzab</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cabanillas</LastName>
<ForeName>Maria E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robinson</LastName>
<ForeName>Bruce</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pacini</LastName>
<ForeName>Furio</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ball</LastName>
<ForeName>Douglas W</ForeName>
<Initials>DW</Initials>
<AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McCaffrey</LastName>
<ForeName>Judith</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Newbold</LastName>
<ForeName>Kate</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Allison</LastName>
<ForeName>Roger</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martins</LastName>
<ForeName>Renato G</ForeName>
<Initials>RG</Initials>
<AffiliationInfo><Affiliation>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Licitra</LastName>
<ForeName>Lisa F</ForeName>
<Initials>LF</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shah</LastName>
<ForeName>Manisha H</ForeName>
<Initials>MH</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bodenner</LastName>
<ForeName>Donald</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Elisei</LastName>
<ForeName>Rossella</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burmeister</LastName>
<ForeName>Lynn</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Funahashi</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Eisai, Andover, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ren</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Brien</LastName>
<ForeName>James P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sherman</LastName>
<ForeName>Steven I</ForeName>
<Initials>SI</Initials>
<AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>08</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Cancer Res</MedlineTA>
<NlmUniqueID>9502500</NlmUniqueID>
<ISSNLinking>1078-0432</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EE083865G2</RegistryNumber>
<NameOfSubstance UI="C531958">lenvatinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C536914">Thyroid cancer, medullary</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018278" MajorTopicYN="N">Carcinoma, Neuroendocrine</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>05</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>08</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26311725</ArticleId>
<ArticleId IdType="pii">1078-0432.CCR-15-1127</ArticleId>
<ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1127</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002432 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002432 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:26311725 |texte= A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26311725" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |